drugset / Trial / NCT01019772

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

NCT01019772

Phase 3 Completed 217 enrolled LG Life Sciences
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate and compare the immunogenicity and safety of LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of Hiberix™ at vaccination in healthy infants at their 2, 4, and 6 months of age.

Timeline

Start
2007-07
Primary completion
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine
Subject LBVH0101 Vaccine